Interpace Biosciences, Inc. (NASDAQ:IDXG)

About the company

Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Sector

Health Services

Industry

Services to the Health Industry

Employees

178

$27.00M

Total Revenue

178

Employees

$20.08M

Market Capitalization

-0.58

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$8M

Operating Margin (in %)

Total operating margin

$-23M

Net Margin (in %)

Total net margin

$-33M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
IQVIA Holdings, Inc. IQV 30169.26 11158.00 5.25 139.79 1.93
Laboratory Corp. of America Holdings LH 18497.50 11587.00 2.61 58.62 2.77
Quest Diagnostics, Inc. DGX 16624.64 7726.00 2.89 19.46 10.33
Syneos Health, Inc. SYNH 6516.88 4720.00 2.15 33.05 4.13
National Research Corp. NRC 1559.48 130.00 40.53 42.84 27.51
Apollo Medical Holdings, Inc. AMEH 600.48 625.00 3.01 33.36 2.89
Protalix Biotherapeutics, Inc. PLX 52.50 66.00 -3.68 -5.56 -14.18
Bioanalytical Systems, Inc. BASI 51.70 55.00 5.16 -22.38 -3.94
Psychemedics Corp. PMD 31.14 35.00 1.81 37.07 2.14
Interpace Biosciences, Inc. IDXG 20.08 27.00 2.97 -0.58 -121.14
Pressure BioSciences, Inc. PBIO 4.50 2.00 -0.52 -0.28 -876.69

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Interpace Biosciences Inc.

5d ago, source: MarketWatch

10/22/2019 N/A S-8 POS Registration Statement 04/30/2018 N/A S-8 Registration Statement 06/13/2017 N/A S-1/A Registration Statement * 06/13/2017 N/A S-1/A Registration Statement * 06/07/2017 N/A S ...

IMMU Continues Ascent, IDXG On Fire, REGN's Kevzara Disappoints In COVID-19 Trial, BLFS On Watch

13d ago, source: Nasdaq

Today's Daily Dose brings you news about BioLife Solutions' preliminary second-quarter revenue estimate; Immunomedics' ...

Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript

20d ago, source: Seeking Alpha

Interpace Biosciences, Inc. (NASDAQ:IDXG) Q1 2020 Earnings Conference Call June 25, 2020 4:30 PM ET Company Participants Jack Stover - President and CEO Fred Knechtel - CFO Conference Call ...

Interpace Biosciences Announces First Quarter 2020 Financial and Business Results

20d ago, source: YAHOO!

PARSIPPANY, NJ, June 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) today announced financial results for the fiscal quarter ended March 31, 2020 and provided a business and ...

20 Healthcare Stocks Moving In Thursday's Pre-Market Session

12d ago, source: MSN

Interpace Biosciences, Inc. (NASDAQ:IDXG) shares rose 17.91% to $5.20. The most recent rating by HC Wainwright & Co., on Jun 26, is at Buy, with a price target of $11. • Chembio Diagnostics ...

IMMU Continues Ascent, IDXG On Fire, REGN's Kevzara Disappoints In COVID-19 Trial, BLFS On Watch

13d ago, source: Business Insider

3. Interpace Biosciences On Fire Interpace Biosciences Inc. (IDXG) has developed COVIANT, a qualitative blood test for the detection of IgG antibodies against SARS-CoV-2 in human plasma and serum.

Interpace Biosciences Announces First Quarter 2020 Financial and Business Results

21d ago, source: Business Insider

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced financial results for the fiscal quarter ended March 31, 2020 and provided a business and financial update. “First quarter revenue was ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.